Cripps AW, Leach AJ, Lehmann D. Pneumococcal vaccination in developing countries[J]. Lancet, 2006, 19, 368(9536): 644.
[2]
Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations[J]. JAMA, 1993, 270(15): 1826-1831.
[3]
WHO position paper. 23-valent pneumococcal polysaccharide vaccine[J]. Wkly Epidemiol Rec, 2007, 82(12): 93-104.
[4]
WHO position paper. 23-valent pneumococcal polysaccharide vaccine[J]. Wkly Epidemiol Rec, 2008, 83(42): 373-384.
[5]
Christenson B, Hedlund J, Lunbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons[J]. Eur Respir J, 2004, 23(3): 363-368.
[6]
Christenson B, Pauksen K, Sylvan SP. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity[J]. Virol J, 2008, 5: 52.
Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial[J]. Lancet, 2005, 365(9465): 1139-1146.
[9]
Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection[J]. N Engl J Med, 2003, 349(14): 1341-1348.
[10]
Christenson B, Lundbergh P, Hedlund J, et al. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study[J]. Lancet, 2001, 357(9261): 1008-1011.
[11]
WHO position paper. Pneumococcal vaccines[J]. Wkly Epidemiol Rec, 2003, 79(14): 110-119.
[12]
Nichol KL, Zimmerman R. Generalist and subspecialist physicians’ knowledge, attitudes and practices regarding influenza and pneumococcal vaccinations for elderly and other high-risk patients[J]. Arch Intern Med, 2001, 161 (22): 270-272.
